LSM-775

One user report at approximately 1.1 mg documented tachycardia, excessive sweating, and elevated blood pressure. LSM-775's pronounced somatic burden at effective doses suggests caution in individuals with pre-existing cardiovascular conditions.

Lithium combined with lysergamides is a recognized seizure risk in psychedelic harm reduction literature. No LSM-775-specific data exist, but the combination is contraindicated by class analogy.

Serotonergic psychedelics act through 5-HT2A agonism on cortical pyramidal neurons, which can trigger psychotic breaks in predisposed individuals. LSM-775's partial 5-HT2A agonism retains this risk despite attenuated hallucinogenic potency.

Serotonergic psychedelics may precipitate manic episodes in individuals with bipolar disorder. LSM-775's attenuated psychedelic potency does not eliminate this risk.

First-degree family history of schizophrenia or other psychotic disorders increases the risk of acute psychotic decompensation with serotonergic psychedelics.

MAOIs prevent serotonin degradation. Combined with LSM-775's full 5-HT1A agonism (EC50 = 1.03 nM, 98% efficacy) and partial 5-HT2A agonism, serotonergic activity could be amplified beyond physiological tolerance, risking severe serotonin syndrome.

Tramadol is a weak serotonin-norepinephrine reuptake inhibitor. Combined with LSM-775's serotonin receptor agonism, the risk of serotonin syndrome is clinically recognized (Beakley et al. 2015). Seed data classifies this interaction as 'dangerous'.

SSRIs and SNRIs increase synaptic serotonin and may interact with LSM-775's direct receptor agonism. A scoping review (Tap et al. 2025) found no confirmed serotonin syndrome cases in psychedelic + antidepressant clinical studies, though most excluded participants on serotonergic medications. Effect attenuation is the more likely outcome.